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A screening for non-target mutations affecting fluoroquinolone susceptibility was
conducted in epidemic multidrug-resistant Salmonella enterica serovar Kentucky ST198.
Among a panel of representative isolates (n = 27), covering the epidemic, only three
showed distinct mutations in ramR resulting in enhanced expression of genes encoding
the AcrAB-TolC efflux system and low increase in ciprofloxacin MIC. No mutations were
detected in other regulatory regions of this efflux system. Ciprofloxacin resistance in
serovar Kentucky ST198 is thus currently mainly due to multiple target gene mutations.
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INTRODUCTION
Fluoroquinolones, together with extended-spectrum
cephalosporins, are the treatment of choice for nontyphoid
salmonellosis, as stable resistance to the most common mem-
bers of different families of antimicrobial agents (ampicillin,
chloramphenicol, streptomycin, sulfonamides, and tetracycline)
has developed during the 1990s with the epidemic Salmonella
enterica serovar Typhimurium phage type DT104 (Cloeckaert
and Schwarz, 2001). Emerging resistance to fluoroquinolones in
Salmonella spp. has been reported for both human and animal
cases and is thus threatening to become a serious public health
problem (Cloeckaert and Chaslus-Dancla, 2001; Piddock, 2002;
Velge et al., 2005; Giraud et al., 2006). Of particular concern is the
international spread of ciprofloxacin-resistant serovar Kentucky
ST198 (Le Hello et al., 2011). This clone is not only highly
resistant to ciprofloxacin but also multidrug-resistant (MDR)
due to the presence of the Salmonella genomic island 1 (SGI1)
carrying a multiple antibiotic resistance gene cluster, mostly
variant SGI1-K carrying another resistance gene cluster (Doublet
et al., 2008; Le Hello et al., 2011). SGI1 was initially identified in
MDR serovar Typhimurium DT104 (Boyd et al., 2001), but nor
the MDR serovar TyphimuriumDT104 clone neither other MDR
S. enterica serovars carrying SGI1 or variants of it, have to our
knowledge been reported to display this high-level ciprofloxacin
resistance.
In Salmonella spp., quinolone/fluoroquinolone resistance is
mostly attributed to point mutations in the quinolone resistance-
determining regions (QRDRs) of the target genes gyrA, gyrB,
parC, and parE. For the gyrA gene, coding for the A subunit of
DNA gyrase, mutations resulting in amino acid changes at Ser83
(to Phe, Tyr, or Ala) or at Asp87 (to Gly, Asn, or Tyr) are the most
frequently observed in nalidixic acid-resistant strains (Cloeckaert
and Chaslus-Dancla, 2001; Piddock, 2002; Velge et al., 2005;
Giraud et al., 2006). High-level fluoroquinolone resistance has
been reported in several S. enterica serovars (Choleraesuis,
Schwarzengrund, Typhimurium) and is essentially due to the
combination of several target gene mutations of which the most
frequent are double mutations resulting in modifications of both
residues 83 and 87 of GyrA together with one mutation leading
to the amino acid change Ser80Ile in the ParC subunit of topoi-
somerase IV (Baucheron et al., 2002, 2004; Chu et al., 2005). In
addition two main other mechanisms have been reported con-
sisting of active afflux mediated by the chromosomally-encoded
AcrAB-TolC efflux system and target protection by Qnr proteins
which are mostly encoded by plasmids acquired by horizontal
transfer (Giraud et al., 2006). However, according to the literature
over 15 years, these mechanisms appear less frequently and thus
from an epidemic point of view seem of lesser importance than
multiple target gene mutations to reach high-level ciprofloxacin
resistance and compromise treatment.
In the case of ciprofloxacin resistance in serovar Kentucky
ST198, three combinations of multiple target modifications,
acquired in a possible sequential way, have been reported con-
sisting of a first GyrA Ser83Phe modification, followed by three
different situations of a second GyrA modification at position
87, i.e., Asp87Asn, Asp87Gly, or Asp87Tyr, and finally the ParC
modification Ser80Ile (Le Hello et al., 2011). Qnr proteins have
not been reported yet as additional mechanism for this epidemic
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Table 1 | Salmonella enterica serovar Kentucky ST198 strains analyzed in this study.
Strain Country Year of Antimicrobial resistance profile SGI1 PFGE type CIP MIC Substitution(s) in Mutation(s) in AcrA
isolation (µg/ml) the QRDR of: efflux pump production
regulatory ratio
regionsGyrA ParC
00 1059 Egypt 2000 AMX NAL + (SGI1-P1) XKEN-1a 0.125 S83F None 3
01 2100 Egypt 2001 AMX STR SPT GEN SUL TET NAL + (SGI1-K1) XKEN-1a 0.125 S83F None – 2
02 2818 Egypt 2002 AMX STR SPT GEN SUL TET NAL + XKEN-1i 0.5 S83F None + (ramR) 5
02 2691 Egypt 2002 AMX STR SPT GEN SUL TET NAL + (SGI1-K3) XKEN-1a 0.125 S83F None – 1
02 8051 Egypt 2002 AMX STR SPT GEN SUL TET NAL + XKEN-1a 0.25 S83F None – 1
02 8141 Egypt 2002 AMX STR SPT GEN SUL TET NAL + (SGI1-K1) XKEN-1m 0.5 S83F None + (ramR) 5
02 9866 Egypt 2002 AMX STR SPT GEN SUL TET NAL CIP + XKEN-1a 8 S83F, D87N S80I – 2
03 9270 India 2003 NAL – XKEN-2d 0.125 S83F None – 1
04 2049 Egypt 2004 NAL CIP + XKEN-1b 8 S83F, D87G S80I – 2
04 4567 Egypt 2004 AMX STR SPT GEN SUL TET NAL CIP + (SGI1-K1) XKEN-1g 4 S83F, D87G S80I – 2
04 6248 Egypt 2004 STR SPT GEN SUL TET NAL CIP + XKEN-1a 8 S83F, D87G S80I – 1
04 7734 Egypt 2004 AMX STR SPT GEN SUL TET NAL + (SGI1-K1) XKEN-1h 0.5 S83F None – 1
04 8262 Egypt 2004 STR SPT GEN SUL NAL CIP + (SGI1-K5) XKEN-1a 8 S83F, D87N S80I – 1
04 9384 Egypt 2004 AMX STR SPT GEN SUL TET NAL CIP + XKEN-1g 4 S83F, D87G S80I – 1
05 0490 Egypt 2005 STR SPT GEN SUL TET NAL CIP + XKEN-1a 4 S83F, D87G S80I – 2
05 0520 Egypt 2005 AMX NAL CIP + (SGI1-P2) XKEN-1a 4 S83F, D87Y S80I – 1
05 1016 Kenya 2005 NAL CIP + (SGI1-Q2) XKEN-1a 4 S83F, D87Y S80I – 1
05 1199 Egypt 2005 STR SPT GEN SUL NAL CIP + (SGI1-Q3) XKEN-1a 4 S83F, D87G S80I – 1
05 2131 Egypt 2005 AMX NAL CIP + (SGI1-Q1) XKEN-1a 4 S83F, D87N S80I – 3
05 2354 Kenya/
Tanzania
2005 AMX STR SPT GEN SUL TET NAL CIP + XKEN-1c 8 S83F, D87Y S80I – 3
05 3290 Egypt 2005 AMX STR SPT GEN SUL TET NAL CIP + XKEN-1c 4 S83F, D87G S80I – 1
05 3883 Kenya/
Tanzania
2005 AMX STR SPT GEN SUL TET NAL CIP + XKEN-1d 4 S83F, D87Y S80I – 2
05 4680 Sudan 2005 STR SPT GEN SUL TET NAL CIP + (SGI1-K4) XKEN-1l 4 S83F, D87G S80I – 2
05 7714 Unknown 2005 AMX NAL CIP + XKEN-1b 4 S83F, D87N S80I – 2
05 8560 Tunisia 2005 AMX STR SPT GEN SUL TET NAL CIP + XKEN-1d 16 S83F, D87N S80I + (ramR) 6
05 236 Egypt 2005 AMX NAL CIP + XKEN-1c 4 S83F, D87N S80I – 1
05 5111 Libya 2005 AMX SUL TET NAL CIP + (SGI1-K2) XKEN-1a 4 S83F, D87N S80I – 1
clone, and active efflux has been suspected in a previous study due
to a moderate increase of production in some isolates of the AcrA
protein belonging to the AcrAB-TolC efflux system (Weill et al.,
2006).
In the present study we assessed the frequency of enhanced
efflux by AcrAB-TolC in a subset of serovar Kentucky ST198
strains of the 2000–2005 period of the epidemic. In case of signif-
icant increased production of AcrAB-TolC we investigated more
deeply the regulatory mechanisms behind this overproduction, in
particular the involvement of the ram, sox, and mar regulatory
loci (Abouzeed et al., 2008; Kehrenberg et al., 2009). Among these
loci, the ramRA locus appears to be the most important in regu-
lating AcrAB-TolC expression in Salmonella spp. (Abouzeed et al.,
2008; Kehrenberg et al., 2009). ramR encodes a repressor protein
(RamR) belonging to the TetR family of repressor proteins, and
has been shown to be the local repressor protein of ramA tran-
scription (Abouzeed et al., 2008; Baucheron et al., 2012); while
ramA encodes a transcriptional activator protein (RamA) belong-
ing to the AraC/XylS family of regulatory proteins (Nikaido
et al., 2008). The latter is involved in upregulating expression
of the AcrAB-TolC system (Nikaido et al., 2008). Several muta-
tions in ramR or its binding site upstream of ramA, affecting
expression of this efflux system, have been detected in clinical
isolates of serovar Typhimurium and of minor serovars Hadar,
Infantis, Livingstone, or Schwarzengrund (Abouzeed et al., 2008;
Kehrenberg et al., 2009; Hentschke et al., 2010; Akiyama and
Khan, 2012).
MATERIALS AND METHODS
The 27 serovar Kentucky ST198 strains selected for this study are
shown in Table 1. Bacterial isolates were selected for this study,
based on their evolutionary history following the emergence of
target gene mutations initially in gyrA at the commencement
of the epidemic in 2000–2002, followed by isolates with addi-
tional mutations (in gyrA and parC) toward the end in 2002–2005
and which demonstrated a higher MIC toward ciprofloxacin.
An additional criterion for selection consisted of the differences
observed in ciprofloxacin MICs suggestive for another resistance
mechanism than target gene mutation. MICs were determined
as described previously (Baucheron et al., 2002, 2004). SGI1
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Table 2 | Primers used for PCRs.
Primer used and Primer Nucleotide position Oligonucleotide Size Annealing References
target region relative to the LT2 sequences(s) (5′ to 3′) (bp) temp (◦)C
strain genome*
DETECTION OF MUTATIONS
ramR-ramA ram5 638085 TCGGTAAAAGGCAGTTCCAG 958 60 This study
ramA6 639042 GTCGATAACCTGAGCGGAAA
acrR-acrA acrR1 533463 CAGTGGTTCCGTTTTTAGTG 992 58 Olliver et al., 2005
acrR2 534454 ACAGAATAGCGACACAGAAA
marC-marO-marR-marA marR1 1597459 CAGTGTTGCGTCTGGACATC 787 60 This study
marR2 1598245 GCTAACGGGAGCAGTACGAC
soxS-soxR sox1 4503970 CTACAGGCGGTGACGGTAAT 915 60 This study
sox2 4504884 CGGCGCTTTAGTTTTAGGTG
acrS-acrE acrS1 3560054 TTGGCATTAATTGCCTCACA 1094 62 This study
acrS2 3561128 ATGATGAATGAGGGCAGGAG
qRT-PCR
gmk gmk-f 3933294 TTGGCAGGGAGGCGTTT 62 60 Baucheron et al., 2012
gmk-r 3933355 GCGCGAAGTGCCGTAGTAAT
gyrB gyrB-f 4040275 TCTCCTCACAGACCAAAGATAAGCT 81 60 Baucheron et al., 2012
gyrB-r 4040195 CGCTCAGCAGTTCGTTCATC
rrs rrs-f NA** CCAGCAGCCGCGGTAAT 57 60 Baucheron et al., 2012
rrs-r NA** TTTACGCCCAGTAATTCCGATT
ramA ramA-f 639180 GCGTGAACGGAAGCTAAAAC 167 60 Baucheron et al., 2012
ramA-r 639346 GGCCATGCTTTTCTTTACGA
acrA acrA-f 533120 GAAACCGCACGTATCAACCT 220 60 Baucheron et al., 2012
acrA-r 532901 CCTGTTTCAGCGAACCATTT
tolC tolC-f 3349107 GCCCGTGCGCAATATGAT 67 60 Baucheron et al., 2012
tolC-r 3349173 CCGCGTTATCCAGGTTGTTG
*GenBank NC_003197.1.
**NA: Not Applicable due to the number of copies of this gene in Salmonella.
detection and characterization were performed as described pre-
viously (Boyd et al., 2001; Doublet et al., 2008). Efflux pump
production was assessed by Dot blot using an anti-AcrA poly-
clonal antibody as described previously (Abouzeed et al., 2008).
Occurrence of mutations affecting acrAB and tolC expression
was determined by PCR and sequencing the regulatory regions
ramR-ramA, acrR-acrA,marC-marO-marR-marA, soxS-soxR, and
acrS-acrE using primers listed in Table 2. Transcription levels of
ramA, acrA, and tolC were determined by qRT-PCR as described
previously (Giraud et al., 2013).
RESULTS AND DISCUSSION
As shown in the Table 1 most of the strains selected carried
SGI1 or variants of it and were thus MDR. They were all from
human cases in France who acquired their infection during
travel to Africa or India. As assessed by Dot blot, most of the
strains (n = 24) did not show significant increased production
of AcrA relative to susceptible serovar Kentucky reference strain
98K (AcrA production ratios from 1 to 2; Table 1). Relative to
strain 98K, three strains showed a 3-fold increased AcrA pro-
duction, and more suggestive for increased active efflux three
strains a 5- to 6-fold increased production of AcrA (Table 1).
Among these regulatory regions, mutations were detected only
in the ramR open reading frame and in only three strains of this
study (Table 3). The mutations were distinct frame shift muta-
tions and consisted of a GATC duplication for strain 02-2818, a
G insertion for strain 05-8560, and a 91 bp deletion for strain
02-8141 (Figure 1). The role of these mutations in upregulating
acrAB and tolC expression, and consecutive enhanced efflux-
mediated resistance, was further assessed by: (i) complementing
with the wild-type ramR gene (using plasmid pRamR Abouzeed
et al., 2008); (ii) determining theMICs of ciprofloxacin and unre-
lated antibiotic florfenicol shown to be substrate of AcrAB-TolC
(Baucheron et al., 2002); and (iii) measuring expression of ramA,
acrA, and tolC by qRT-PCR (Giraud et al., 2013). The results
shown in Table 3 are in agreement with data published previously
for other S. enterica serovars (Abouzeed et al., 2008; Kehrenberg
et al., 2009), i.e. ramR mutations observed account for a 2- to 4-
fold increased resistance level by active efflux through enhanced
expression of AcrAB-TolC. As also observed in previous studies,
the effect of such mutations on ramA transcription level was sig-
nificantly higher than on acrA or tolC transcription levels. It is
somehow expected considering the direct local repressor activity
of RamR on ramA transcription and the distant RamA transcrip-
tional activator activity on acrAB and tolC (Abouzeed et al., 2008;
Baucheron et al., 2012; Giraud et al., 2013).
Non-target mutations as assessed in this study confirm
they are infrequent in Salmonella spp. but seem nevertheless
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FIGURE 1 | Mutations detected in the ramR-ramA region relative to the genome sequence of S. enterica serovar Kentucky strain CDC 191 (GenBank:
ABEI01000007.1).
mostly restricted to the ram regulatory region. Most muta-
tions in the ramR-ramA region reported to date, as also
shown in this study, are distinct and found in single iso-
lates. To our knowledge only independent isolates of the epi-
demic ciprofloxacin-resistant serovar TyphimuriumDT204 clone
from the 1990s have been shown to carry the same muta-
tion in ramR consisting of an insertion by an IS1 element
(Abouzeed et al., 2008). We may nevertheless expect that the
further global spread of ciprofloxacin-resistant serovar Kentucky
ST198 and its resistance evolution will possibly, like in the
case of serovar Typhimurium DT204, result in successful ramR-
mutation-carrying subclones.
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